For example, soluble E-cadherin has been employed as one of the markers of EMT and tumor invasion in a phase I clinical trial in non-small cell lung cancer (NSCLC) patients [42], phase II trial in gastric cancer patients [43], and phase II trial in metastatic renal cell carcinoma patients [44]. Here, CDH1 is linked to non-small cell lung carcinoma.